{"nctId":"NCT00404651","briefTitle":"Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants","startDateStruct":{"date":"2006-11"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Poliomyelitis"],"count":1189,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-IPV-HB-PRP~T vaccine"]},{"label":"Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-IPV-HB-PRP~T vaccine"]},{"label":"Group 3","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-IPV-HB-PRP~T vaccine"]},{"label":"Group 4","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: DTaP-HBV-IPV vaccine"]}],"interventions":[{"name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"name":"DTaP-HBV-IPV vaccine","otherNames":["INFANRIX®HEXA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Two months old infants on the day of inclusion\n* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg\n* Informed consent form signed by one or both parents or by the guardian and two independent witnesses\n* Able to attend all scheduled visits and to comply with all trial procedures\n* Received Bacillus Calmette Guerin (BCG) vaccine between birth and one month of life in agreement with the national immunization calendar.\n\nExclusion Criteria :\n\n* Participation in another clinical trial in the four weeks preceding the (first) trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Congenital or acquired immunodeficiency\n* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances\n* Chronic illness at a stage that could interfere with trial conduct or completion\n* Blood or blood-derived products received since birth\n* Any vaccination in the four weeks preceding the first trial visit\n* Any planned vaccination (except BCG, rotavirus, and pneumococcal conjugated vaccines) during the study\n* Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically)\n* Previous vaccination against hepatitis B, pertussis, tetanus, diphtheria, poliovirus, or Haemophilus influenzae type b infection(s)\n* Known personal or maternal history of HIV, Hepatitis B (HBsAg) or Hepatitis C seropositivity\n* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination\n* History of seizures\n* Febrile (rectal equivalent temperature ≥ 38.0°C) or acute illness on the day of inclusion.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine","description":"Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for Diphtheria (D) by toxin neutralization test, and for Tetanus (T) by enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as a titer ≥ 0.10 mIU/mL for Hep B, ≥ 0.15 µg/mL for PRP, and ≥ 0.01 IU/mL for D and T antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"231","spread":null},{"groupId":"OG002","value":"221","spread":null},{"groupId":"OG003","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"232","spread":null},{"groupId":"OG002","value":"226","spread":null},{"groupId":"OG003","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"228","spread":null},{"groupId":"OG002","value":"222","spread":null},{"groupId":"OG003","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"236","spread":null},{"groupId":"OG002","value":"227","spread":null},{"groupId":"OG003","value":"119","spread":null}]}]}]},{"type":"PRIMARY","title":"Equivalence of Seroprotection Against Pertussis in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine.","description":"Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as a ≥ 4 fold increase in titer from Day 0 (before dose 1) to Day 150, one month post-dose 3.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"226","spread":null},{"groupId":"OG002","value":"218","spread":null},{"groupId":"OG003","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":null},{"groupId":"OG001","value":"229","spread":null},{"groupId":"OG002","value":"216","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]}]},{"type":"PRIMARY","title":"Equivalence of Seroprotection Against Poliovirus Types 1, 2, and 3 in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine","description":"Antibody titers were measured for poliovirus types 1, 2, and 3 by Enzyme immuno assay. Seroprotection against Poliovirus Types 1, 2, and 3 was defined as a titer ≥ 8 (1/dilutions).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"236","spread":null},{"groupId":"OG002","value":"225","spread":null},{"groupId":"OG003","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"236","spread":null},{"groupId":"OG002","value":"226","spread":null},{"groupId":"OG003","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"226","spread":null},{"groupId":"OG003","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Antibodies After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine","description":"Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria (D) by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay. Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by enzyme linked immunosorbent assay (ELISA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"935","spread":null},{"groupId":"OG001","value":"1566","spread":null},{"groupId":"OG002","value":"1009","spread":null},{"groupId":"OG003","value":"1576","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"13.1","spread":null},{"groupId":"OG002","value":"11.5","spread":null},{"groupId":"OG003","value":"6.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.176","spread":null},{"groupId":"OG001","value":"0.246","spread":null},{"groupId":"OG002","value":"0.173","spread":null},{"groupId":"OG003","value":"0.173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":null},{"groupId":"OG001","value":"1.86","spread":null},{"groupId":"OG002","value":"1.77","spread":null},{"groupId":"OG003","value":"2.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"860","spread":null},{"groupId":"OG001","value":"945","spread":null},{"groupId":"OG002","value":"843","spread":null},{"groupId":"OG003","value":"1370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1689","spread":null},{"groupId":"OG001","value":"1665","spread":null},{"groupId":"OG002","value":"1612","spread":null},{"groupId":"OG003","value":"2337","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1198","spread":null},{"groupId":"OG001","value":"1170","spread":null},{"groupId":"OG002","value":"962","spread":null},{"groupId":"OG003","value":"2186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG002","value":"241","spread":null},{"groupId":"OG003","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"256","spread":null},{"groupId":"OG002","value":"220","spread":null},{"groupId":"OG003","value":"182","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site or Systemic Reactions After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T Vaccine or Infanrix Hexa™ Vaccine","description":"Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Fever (\\[pyrexia\\] - temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"237","spread":null},{"groupId":"OG002","value":"225","spread":null},{"groupId":"OG003","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"220","spread":null},{"groupId":"OG002","value":"199","spread":null},{"groupId":"OG003","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"209","spread":null},{"groupId":"OG002","value":"198","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"101","spread":null},{"groupId":"OG003","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"82","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"156","spread":null},{"groupId":"OG002","value":"148","spread":null},{"groupId":"OG003","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"134","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"122","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"102","spread":null},{"groupId":"OG003","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"198","spread":null},{"groupId":"OG002","value":"193","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"192","spread":null},{"groupId":"OG002","value":"174","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"167","spread":null},{"groupId":"OG002","value":"165","spread":null},{"groupId":"OG003","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":337},"commonTop":["Injection Site Pain","Irritability","Crying","Somnolence","Injection Site Erythema"]}}}